Total revenue for the period came in at $49.7 million, up 27.6% y-o-y from $38.9 million previously, due to a rise in demand for the group’s Health and Diagnostics and Aesthetics services for 1HFY2021 as compared to 1HFY2020 where operations were significantly curtailed due to the Circuit Breaker (“CB”) period in Singapore from April to June 2020.
Catalist-listed Singapore Medical Group (SMG) has reported earnings of $7.2 million for the 1HFY2021 ended June, an increase of 108.2% y-o-y.
This translates to earnings per share (EPS) of 1.49 cents for the 1HFY2021, compared to 0.79 cents the year before.
